GlassScriptPhysician profile
Christopher D Mcclung
NPI 1285804252
$10,113.15
in general payments reported to CMS, 2019-2025
13 companies · $43.23 in 2025
The $43.23 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $48.29 · 2021: $4,715 · 2022: $78.82 · 2023: $3,896 · 2024: $1,195 · 2025: $43.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,134.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $5,056.93 | 2023-2024 | M22 |
| Boston Scientific Corporation | $4,717.79 | 2019-2022 | |
| Myovant Sciences INC. | $54.39 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $45.63 | 2022 | |
| Baxter Healthcare | $37.02 | 2023-2025 | Artiss |
| Endo Pharmaceuticals INC. | $31.17 | 2019-2020 | |
| Abbvie INC. | $28.98 | 2019-2020 | |
| Astellas Pharma US INC | $28.82 | 2019-2021 | |
| Blue Earth Diagnostics | $27.75 | 2021 | |
| 180 Medical, INC. | $25.55 | 2021 | |
| Ethicon US, LLC | $22.23 | 2025 | Surgiflo Hemostatic Matrix |
| Neotract INC. | $18.92 | 2020 | |
| Kerecis Limited | $17.97 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Mcclung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.